Thyrogen (Thyrotropin Alfa) — CPB 0515 | AETNA Coverage Update

Aetna, a CVS Health company, modified CPB 0515 covering Thyrogen (thyrotropin alfa) billing, effective January 5, 2026. Here's what billing teams need to know.

Aetna updated its Thyrogen coverage policy under CPB 0515 Aetna system, refining medical necessity criteria for thyrotropin alfa (HCPCS J3240) across three covered indications for differentiated thyroid carcinoma and non-toxic multinodular goiter. The policy also maintains a hard exclusion for patients with suppressed serum thyroglobulin below 0.1 ng/ml, which is a common claim denial trigger your billing team needs to catch before submission. If your practice bills CPT 84432 (thyroglobulin) or CPT 78015–78018 (thyroid carcinoma metastases imaging) alongside J3240, this policy change directly affects your charge capture and documentation requirements.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Thyrogen (Thyrotropin Alfa) — CPB 0515
Policy Code	CPB 0515
Change Type	Modified
Effective Date	January 5, 2026
Impact Level	Medium
Specialties Affected	Endocrinology, Nuclear Medicine, Oncology, Radiation Oncology
Key Action	Audit J3240 claims for suppressed Tg documentation before submission; confirm ICD-10 C73 or E04.2 is on file

---

Aetna Thyrogen Coverage Criteria and Medical Necessity Requirements 2026

Aetna's Thyrogen coverage policy under CPB 0515 covers thyrotropin alfa for three distinct clinical scenarios. Each has its own medical necessity standard, and mixing up the documentation requirements across these groups is exactly how claims get denied.

Group 1: Tg Testing and Radioiodine Imaging

Aetna covers J3240 as a substitute for thyroid hormone withdrawal when a patient with differentiated thyroid carcinoma meets any one of five criteria:

The fifth criterion is worth highlighting. It's the one most billing teams miss. If the patient has undetectable Tg on suppression but the physician wants to exclude residual disease, Thyrogen is covered. That's a specific clinical scenario—document it exactly that way in the medical record.

Group 2: Radioiodine Ablation After Surgery

Aetna considers Thyrogen medically necessary to prepare a patient for radioiodine ablation of remnant thyroid tissue after surgery for differentiated thyroid carcinoma. This is covered as an alternative to thyroid hormone withdrawal, not an addition to it. Your documentation should reflect that withdrawal was bypassed intentionally, not skipped inadvertently.

Group 3: Non-Toxic Multi-Nodular Goiter

Aetna covers thyrotropin alfa as an adjunct to radioiodine ablation for non-toxic multi-nodular goiter. This is the only covered non-cancer indication. ICD-10 E04.2 is the correct diagnosis code for this group. Bill anything else for goiter and expect a denial.

Dosing and Administration

The covered dosing regimen is two intramuscular injections of Thyrogen 0.9 mg, given 24 hours apart. Charge capture should reflect J3240 billed twice (one unit = 0.9 mg per 1.1 mg vial). Deviating from this regimen—billing a single injection, for example—creates a documentation mismatch that invites audits.

Prior Authorization

CPB 0515 does not spell out a prior authorization requirement in the policy text itself, but Thyrogen (thyrotropin alfa) is a specialty injectable that typically triggers prior auth review under most Aetna commercial plans. Confirm prior authorization requirements with the specific plan before administering. Don't assume the absence of a stated PA requirement means PA is not needed.

A Note on Reimbursement

For Medicare patients, Aetna directs you to Medicare Part B criteria—not this CPB. Don't apply CPB 0515 criteria to Medicare Advantage claims without checking whether the plan follows Medicare Part B billing guidelines or has additional restrictions. The reimbursement rules differ, and conflating the two is a real exposure point.

---

Aetna Thyrogen Exclusions and Non-Covered Indications

Aetna considers thyrotropin alfa experimental, investigational, or unproven for patients with differentiated thyroid cancer who have suppressed serum thyroglobulin below 0.1 ng/ml. Full stop.

This exclusion sits directly adjacent to covered indication five (undetectable Tg on suppressive therapy to exclude residual cancer). The difference is clinical and documentation-dependent. Covered: undetectable Tg where the physician is actively ruling out residual disease. Not covered: suppressed Tg below 0.1 ng/ml as a standalone lab finding without that specific clinical rationale documented.

If a claim for J3240 comes back denied under "insufficient evidence of effectiveness," look at the Tg value in the chart. If it's below 0.1 ng/ml and the physician's note doesn't articulate the exclusion rationale, that denial is accurate under this policy. The fix is upstream—at documentation, not billing.

---

Coverage Indications at a Glance

---

Aetna Thyrogen Billing Guidelines and Action Items 2026

The effective date for this modified policy is January 5, 2026. Claims for dates of service on or after that date fall under these updated criteria. Here's what your billing team should do now.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Thyrogen (Thyrotropin Alfa) Under CPB 0515

HCPCS Code — Primary Billing Code (Covered When Criteria Are Met)

Code	Type	Description Copy
J3240	HCPCS	Injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial

CPT Codes Related to CPB 0515

These codes are associated with the clinical workup and imaging performed alongside Thyrogen administration. They're not standalone covered codes for Thyrogen itself—they're the procedures that Thyrogen facilitates.

Key ICD-10-CM Diagnosis Codes

Code	Description	Notes Copy
C73	Malignant neoplasm of thyroid gland	Covered — except for suppressed serum Tg < 0.1 ng/ml
E04.2	Nontoxic multinodular goiter	Covered — adjunct to radioiodine ablation only
Z85.850	Personal history of malignant neoplasm of thyroid	Covered — post-treatment surveillance context

---